Shares of biotech companies rose Monday after Pfizer announced a $14 billion deal to acquire cancer drug manufacturer Medivation. Given the news, the rally in the sector may not be over, if history is any guide.
Since 2002, there have been seven major acquisitions by Pfizer, all valued at more than $1 billion.
According to data from Kensho, a quantitative tool used by hedge funds to spot historical trading patterns, a group of companies could be in for some gains.
Here's what we found.